We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA announced full approval of Teva’s generic naloxone nasal spray—tentatively approved last June as the first generic spray for treating opioid overdoses—and said the agency will prioritize reviews of other naloxone generics and push for the development of an over-the-counter version. Read More